Revvity Inc. stock (US76155R1086): shares edge higher ahead of next earnings update

Revvity Inc. shares on the NYSE ticked higher in recent trading, with investors looking toward the next quarterly update after the life science tools company reported flat organic revenue and lower earnings in its latest quarter. Valuation metrics remain in focus going into the second half of 2026.

Revvity Inc. shares traded modestly higher on the New York Stock Exchange in recent sessions, with the stock changing hands at about USD 102.38 as of 06/04/2026, according to MarketBeat as of 06/04/2026. The United States-based life science tools group, listed under the ticker RVTY on the NYSE, remains in focus after its most recent earnings report showed weaker profitability alongside subdued top-line trends.

The stock, which started 2026 at around USD 96.81, has gained roughly 5.8 percent year to date based on the same MarketBeat price data as of 06/04/2026, suggesting a moderate recovery as investors digest the company’s latest quarterly figures and await new guidance from management.

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Revvity Inc.
• Sector/industry: Life sciences tools and diagnostics
• Headquarters/country: Waltham, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Diagnostic instruments and reagents, life science research tools, genomics and imaging solutions
• Home exchange/listing venue: New York Stock Exchange (RVTY)
• Trading currency: USD

Revvity Inc.: core business model

Revvity Inc. operates as a provider of laboratory technologies and diagnostic solutions, supplying instruments, consumables, and software that support research, clinical testing, and applied markets across genomics, reproductive health, and specialty diagnostics.

Valuation metrics and multiples for Revvity Inc.

Valuation has been a key discussion point for Revvity Inc. since the company’s portfolio reshaping and rebranding from PerkinElmer, with investors monitoring earnings power and growth visibility in the core life science and diagnostics businesses. As of 06/04/2026, MarketBeat reported a share price of USD 102.38 for RVTY and noted that the stock had advanced about 5.8 percent in 2026 after opening the year near USD 96.81, providing the base level for standard valuation ratios at current trading levels, according to MarketBeat as of 06/04/2026.

Revvity is commonly viewed alongside other established life science tools and diagnostics companies when investors compare valuation multiples, with the company’s mix of recurring consumables, instruments, and software influencing the balance between growth expectations and margin resilience. MarketBeat also highlights that RVTY carries a consensus Hold rating across analysts as of 06/04/2026, summarizing that the average recommendation remains neutral while the market waits for clearer evidence of accelerating revenue growth and sustained earnings expansion.

Conclusion

Revvity Inc. shares on the NYSE are trading modestly above their level at the start of 2026, with a price of about USD 102.38 as of 06/04/2026 framing the current valuation in the context of recent earnings and portfolio changes. Neutral analyst sentiment and a consensus Hold stance underline that the market is watching for stronger revenue momentum and margin improvement before re-rating the life science tools group more aggressively. Investors following the stock are likely to focus on upcoming quarterly updates and any strategic commentary that might shift expectations for growth, profitability, and cash generation in the company’s core diagnostics and research businesses.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.